CORONARITIS IN RHEUMATIC DISEASES: A LITERATURE REVIEW


如何引用文章

全文:

详细

The article analyzes data of domestic and foreign literature devoted to the problem of coronaritis in patients with rheumatic diseases. The significance of atherosclerosis and its complications in rheumatic diseases, as well as methods of diagnosis and treatment in these patients are discussed.

参考

  1. Gunal N, Baysal K, Haciomeroglu P, et al. Rheumatic heart disease and coronary vasculitis in children. Acta Paediatrica 2006;1:118-20.
  2. Kruczan DD, Silva NA, Pereira Bde B, et al. Coronary artery disease in patients with rheumatic and non-rheumatic valvular heart disease treated at a public hospital in Rio de Janeiro. Arq Bras Cardiol 2008;90(3):197-203.
  3. Моисеев В.С., Моиссев С.В., Кобалава Ж.Д. Болезни сердца. М., 2008. 528 с.
  4. Mandel BF, Hoffman GS. Rheumatic diseases and the cardiovascular system. In: Zippes PD, Libby P, Bonow OR, (Eds.). In Braunwald's Heart disease: a textbook of cardiovascular medicine, International. 7th. Elsevier Saunders, 2005:2101-16.
  5. Urowitz MB, Bookman AM, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221-25.
  6. Дряженкова И.В. Поражение сердечно-сосудистой системы при ревматических заболеваниях // Кардиология 2005. № 11. С. 98-101.
  7. Шилкина Н.П., Дряженкова И.В. Системные васкулиты и атеросклероз // Терапевтический архив 2007. № 3. С. 84-92.
  8. Ревматология. Клинические рекомендации / Под ред. Е.Л. Насонова. М., 2010. 738 с.
  9. Мухин Н.А., Лысенко Л.В., Козловская Н.Л. Поражение почек при антифосфолипидном синдроме // Врач 2002. № 6. C. 13-8.
  10. Насонов Е.Л. Антифосфолипидный синдром. М., 2004. 440 c.
  11. Стрижаков Л.А., Козловская Н.Л., Паша С.П. и др. Клиническое значение поражения миокарда при антифосфолипидном синдроме // Клиническая медицина 2006. № 4. С. 56-9.
  12. Leibovitz W. The heart in rheumatoid arthritis. Ann Int Med 1963;58:102.
  13. Banks M, Flint J, Bacon PA, et al. Rheumatoid arthritis is an independent risk factor for ischaemic heart disease wabstractx. Arthritis Rheum 2000;43:385.
  14. Goodson NJ, Wiles NJ, Lunt M. Mortality in early inflammatory polyartritis. Cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002;46:2010-19.
  15. Jenette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
  16. Endo M, Tomizawa Y, Nishida H, et al. Angiographic findings and surgical treatments of coronary artery involvement in Takayasu arteritis. J Thorac Cardiovasc Surg 2003;125:570-77.
  17. Arima M, Kanoh T, Kawano Y, et al. Isolated Coronary ostial stenosis associated with coronary vasospasm. Japanese Circulation J 2000;64:985-87.
  18. Seyahi E, Ugurlu S, Cumali R, et al. Atherosclerosis in Takayasu arteritis. Ann Rheum Dis 2006;65(9):1202-207.
  19. Тареев Е.М. Коллагенозы. М., 1965. 380 c. Schrader M, Hochman J, Bulkley B. The heart in poltarteritis nodosa: a clinicopathologic study. Am Heart J 1985;109:1353-59.
  20. Rajani RM, Dalvi BV, D'Silva SA, et al. Acute myocardial infarction with normal coronary arteries in a case of polyarteritis nodosa: possible role of coronary artery spasm. Postgraduate Medical J 1991;67:78-80.
  21. Семенкова Е.Н., Моисеев С.В., Наместникова О.Г. Клинические аспекты синдрома гиперэозинофилии // Клиническая медицина 2004. № 2. С. 28-31.
  22. Гиляревский С.Р. Миокардиты: современные подходы к диагностике и лечению. М., 2008. 328 c.
  23. Renaldini E, Spandrio S, Cerudelli B, Affatato A, et al. Cardiac involvement in Charge-Strauss syndrome: a follow-up of three cases. European Heart Journal 1993;14:112-21.
  24. Lanham JG, Churg J. Churg-Strauss syndrome. Systemic vasculitides. Ed. Churg A, Churg J. New York, 1991:101-20.
  25. Lanham JG, Elkon KB, Pusey CD, et al. Systemic vasculitis with astma and eosinopholia: a clinical approach to the Churg Strauss syndrome. Medicine (Baltimore) 1984;63:65-81.
  26. Lie JT, Bayardo RJ. Isolated eosinophilic coronary arteritis and eosinophilic myocarditis. A limited form of Churg-Strauss syndrome. Arch Path Lab Med 1989;2:199-201.
  27. McGavin CR, Marshall AJ, Lewis CT. Churg-Strauss syndrome with critical endomyocardial fibrosis: 10 year survival after combined surgical and medical management. Heart 2002;5:5
  28. Korantzopoulos P, Papaioannides D, Siogas K. The Heart in Wegener's Granulomatosis. Cardiology 2004;102:7-10.
  29. Parry SD, Clark DM, Campbell J. Coronary arteritis in Wegener's granulomatosis causing fatal myocardial infarction. Hosp Med 2000;61:284-85.
  30. Lazarus MN, Khurana R, Sethi AS, Naughton MA. Wegener's granulomatosis presenting with an acute ST-elevation myocardial infarct (STEMI). Rheumatology (Oxford) 2006;45:916-18.
  31. Sarlon G, Durant C, Grandgeorge Y, et al. Manifestations cardiaques au cours la granulomatose de Wegener: à propos de quatre observations et revue de la literature. La Revue de médecine interne 2010;31:135-39.
  32. Faurschou M, Mellemkjaer L, Sorensen I, et al. Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis. Arthritis Rheum 2009;60(4):1187-92.
  33. Моисеев С.В., Стрижаков Л.А., Диттерле В.Е., Кузнецова Е.И. Частота сердечно-сосудистых заболеваний у пациентов с системными васкулитами // Клиническая фармакология и терапия 2011. Т. 20. № 3. С. 30-4.
  34. Chironi G, Pagnoux C, Simon A, et al. Increased prevalence of subclinical atherosclerosis in patients with small-vessel vasculitis. Heart 2007;93:96-9.
  35. Choi HK, Hernan MA, Seeger JD. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-77.
  36. Booth AD, Jayne DRW, Kharbanda RK, et al. Infliximab Improves Endothelial Dysfunction in Systemic Vasculitis. Circulation 2004;109:1718-23.
  37. Raza K, Thambyrajah J, Townend JN, et al. Suppression of Inflammation in Primary Systemic Vasculitis Restores Vascular Endothelial Function: Lessons for Atherosclerotic Disease? Circulation 2000;102(13):1470-2.
  38. Jacobsson LT, Askling J, Rantapaa-Dahlvist S. Anti-TNF therapy and risk of death up to 8 years after treatment start. Results from the Swedish biologics register (ARTIS) Ann Rheum Dis 2008;67:183.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2012